Since its introduction to the market in 2012, Unyvero has been brought into numerous hospital laboratories and intensive care units throughout Europe. Leading clinical experts have tested the system and now appreciate the advantages of the Unyvero Solution in everyday clinical use.
Curetis’ Subsidiary Ares Genetics Advances AI-powered Infectious Disease and Antibiotic Resistance Test
Curetis’ Subsidiary Ares Genetics Teams Up with Leading Global Pharma Company in Fight Against Antibiotic Resistance
Reanimation Congress 2019 - Paris, France - 23 to 25 January, 2019
29. Symposium Intensivmedizin + Intensivpflege - Bremen, Germany - 20 to 22 February, 2019